miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

Simple item page
dc.contributor.authorRomero Lorca, Alicia
dc.contributor.authorNovillo Villajos, Apolonia
dc.contributor.authorGaibar Alonso, María
dc.contributor.authorGilsanz Muñoz, María Fuencisla
dc.contributor.authorGalán Burgos, Miguel
dc.contributor.authorBeltrán, Laura
dc.contributor.authorAntón, Beatriz
dc.contributor.authorMalón, Diego
dc.contributor.authorMoreno, Amalia
dc.contributor.authorFernández Santander, Ana
dc.date.accessioned2026-02-03T11:53:01Z
dc.date.available2026-02-03T11:53:01Z
dc.date.issued2021
dc.description.abstractBevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It is currently used in combination with chemotherapy to treat metastatic colorectal cancer. This therapy is not equally effective in every patient; in some, mechanisms of resistance arise that remain poorly understood. The aim of the present work was to determine whether the expression of 26 miRNAs could be associated with the effectiveness of bevacizumab plus chemotherapy, with progression-free survival (PFS), and with overall survival (OS) in metastatic colorectal cancer.en
dc.description.filiationUEM
dc.description.impact2.606 Q3 JCR 2024
dc.description.impact0.683 Q2 SJR 2024
dc.description.impactNo data SJR 2024
dc.description.sponsorshipUniversidad Europea de Madrid 2016/UEM13
dc.identifier.citationRomero-Lorca, A., Novillo, A., Gaibar, M., Gilsanz, M. F., Galán, M., Beltrán, L., Antón, B., Malón, D., Moreno, A., & Fernández-Santander, A. (2021). Mir-7, mir-10a and mir-143 expression may predict response to bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. Pharmacogenomics and Personalized Medicine, Volume 14, 1263-1273. https://doi.org/10.2147/PGPM.S313594
dc.identifier.doi10.2147/PGPM.S313594
dc.identifier.issn1178-7066
dc.identifier.urihttps://hdl.handle.net/11268/16780
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttps://doi.org/10.2147/PGPM.S313594
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherNeoplasias Colorrectales
dc.subject.otherAdhesión en Parafina
dc.subject.otherSupervivientes de Cáncer
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.unescoCáncer
dc.subject.unescoInvestigación médica
dc.subject.unescoTecnología médica
dc.titlemiR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Canceren
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication6df66eed-0c97-49a7-87e4-7052fb851239
relation.isAuthorOfPublication4b02f8da-816e-471d-b72b-000a5a37e0da
relation.isAuthorOfPublicationd6fe9d38-0315-4e3c-974d-4b4a568ba81e
relation.isAuthorOfPublication8f0ff816-e791-403f-901d-e479575cf9e8
relation.isAuthorOfPublication.latestForDiscovery6df66eed-0c97-49a7-87e4-7052fb851239

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
miR-7, miR-10a and miR-143_2026.pdf
Size:
957.35 KB
Format:
Adobe Portable Document Format
Download

Collections

Área de Biotecnología y Biología Molecular